We present two patients with a high viral load of HIV-1 who developed symptoms of ascending paralysis leading to respiratory failure and autonomic instability. One patient had symptom improvement with highly active antiretroviral therapy (HAART) and a subsequent decrease in viral load. The other patient improved with intravenous immunoglobulin therapy and did not show much improvement on HAART alone. There are several proposed mechanisms for peripheral neuropathies seen in HIV-infected patients, including a direct action of HIV on the nerve by neurotropic strains or formation of autoantibodies against nerve elements. The comparison of the response to different therapies in these two cases highlights the importance of understanding different pathophysiologies, as the treatment modality may differ.
A bout 34 million people are aff ected with HIV worldwide as of 2010, including more than 1.1 million in the United States (1) . Th e immune impairment manifests clinically in multiple organ systems including the nervous system. Since the introduction of highly active antiretroviral therapy (HAART), HIV has evolved into a chronic condition with an increase in related complications (2) . Neurologic complications occur in more than 40% of patients with HIV infection, and the prevalence of neuropathologic fi ndings at autopsy is about 80% (3, 4) . Central and peripheral nervous system involvement in HIV-infected patients occurs due to various causes, including opportunistic infections, immune reconstitution, a side eff ect of antiretroviral medication, or the eff ect of the virus (5) . Th e variations might be due to a diff erence in age, disease stage, treatment history, timing of the study (i.e., pre-or post-HAART era), and the diagnostic criteria used in diff erent studies. We present two cases of ascending paralysis in HIV-positive patients. Not only was the autoimmune nature of Guillain-Barré syndrome (GBS) in the setting of an immunocompromised patient remarkable, but more importantly the improvement seen in both patients required diff erent treatment approaches.
CASE 1
A 33-year-old white man presented with a 1-day history of bilateral lower-extremity weakness, numbness, and a tingling sensation that started in his feet and progressed to his knees and very soon involved his fi ngertips bilaterally. Th e patient was diagnosed with HIV 1 week earlier during evaluation of a fl ulike illness including fever, chills, and maculopapular rash with diarrhea. His HIV viral load was 2,095,380 copies/mL, with a CD4 count of 526 cells/μL (Table 1) . Baseline genotype testing done at that time showed no drug resistance. His past medical history was unremarkable. Examination disclosed intact cognition, intact cranial nerves, decreased sensation in the lower extremities bilaterally up to the knees, along with decreased sensation on the palmar aspect of the hands bilaterally. Muscle strength was slightly decreased bilaterally in the sion. Four days after intubation, the patient fairly quickly recovered his respiratory muscle strength and was extubated. A repeat HIV viral load test after 1 week of HAART showed only 3590 copies/mL. A nerve conduction study (NCS) and electromyogram (EMG) performed 15 days after presentation showed evidence of an acquired sensory and motor peripheral neuropathy with mixed axonal and demyelinating features. Th ere was also diffuse early denervation indicating secondary axonal loss. Th e relative paucity of denervation seen on the EMG/NCS exam likely refl ected the short time lapse since the onset of symptoms.
Th e patient continued to gradually regain his muscular function and was transferred to a skilled nursing facility for continuing physical therapy. After a 4-week stay at the facility, his muscle strength was close to baseline, and he was discharged home.
CASE 2
A 37-year-old white man with a history of HIV/AIDS with a last CD4 count of 22 cells/μL (Table 1) presented to the emergency department with 4 weeks of progressively worsening ascending weakness, tingling, and numbness of his lower extremities, with gradual involvement of his upper extremities. He had a history of recurrent lower-extremity weakness and decreased sensation that had required previous hospitalizations. His past medical history was signifi cant for anemia, several episodes of gastritis, asthma, past hepatitis B infection, and anxiety. His family history was not signifi cant for any neurological diseases. Examination disclosed a cognitively intact man with intact cranial nerves. Th ere was a lack of sensation to light touch in the feet and numbness in the hand bilaterally. Grip strength was weak in both hands with trace fi nger abduction. Elbow fl exion and extension was 3/5 and shoulder fl exion was 2/5. Refl exes were absent in both upper and lower extremities. MRI scans of the brain and spine were unremarkable. CSF evaluation revealed classic albuminocytologic dissociation without any signs of active infection (Table 2) .
NCS and EMG tests 20 days after hospitalization showed diff use sensory motor polyneuropathy with both demyelinating and axonal features. Th e patient was started on HAART with Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) and given 2 days of IVIG. Soon after starting IVIG, the patient showed clinical improvement. He was transferred for rehabilitation after a 1-week hospital stay for aggressive physical therapy. Since his initial presentation about a year ago, he has been rehospitalized twice with similar symptoms despite being on continual HAART, during which his viral load has been very low (varying from <20 copies/mL up to 1510 copies/mL). His symptoms continue to respond to treatment with IVIG. Repeated CSF evaluations reveal cytoalbuminologic dissociation at varying degrees (white cells range from 2 to 8 /μL, and protein ranges from 114 to 331 mg/dL). Although the patient started out with AIDP with axonal features, he now carries the diagnosis of chronic infl ammatory demyelinating polyneuropathy (CIDP).
deltoids. Patellar, Achilles, and biceps deep tendon refl exes were absent, with only the triceps jerk detected at presentation. Cerebrospinal fl uid (CSF) analysis in the emergency department showed elevated proteins with mild lymphocytic pleocytosis ( Table 2 ). Based on his presentation and CSF fi ndings, he was started on intravenous immunoglobulin (IVIG) the day of admission for possible acute infl ammatory demyelinating polyneuropathy (AIDP). Within the fi rst few days of admission, he was also started on HAART with Truvada, raltegravir, darunavir, and ritonavir. Th e CSF was positive for mycoplasma IgG antibodies (1:4 titer) with negative IgM. However, the test for serum mycoplasma IgM was positive, and hence the patient was started on levofl oxacin. Th e results of magnetic resonance imaging (MRI) of the brain and cervical spine without contrast were unremarkable.
Th e patient's ascending paralysis worsened over the next 3 days with paresthesias, loss of all deep tendon refl exes, and involvement of cranial nerves. He completed a full course of IVIG of 2 g/kg over 3 days but continued to deteriorate and was started on a fi ve-cycle regimen of plasmapheresis on day 5. Despite aggressive daily plasmapheresis for three cycles, he continued to worsen with autonomic instability, fl accid quadriplegia, and respiratory failure requiring endotracheal intubation and mechanical ventilation 8 days after admis- 
DISCUSSION
Th ese two cases of HIV illustrate very similar clinical presentations with very diff erent pathophysiologies and long-term outcomes. Th e CSF and HIV status fi ndings dictated very different treatment regimens. In case 1, the patient had aseptic meningitis with multiple possible etiologies (HIV, mycoplasma, seroconversion) and improved only after his HIV RNA titers came down in a monophasic pattern of illness. In the second case, the patient did not have meningitis but rather had what is now known to be CIDP with recurrent symptoms responding very well to IVIG.
HIV can be neuroinvasive, neurotropic, and neurovirulent. Many peripheral neuropathic syndromes have been reported in the context of HIV infection, including HIV-associated distal sensory neuropathy, neurotoxic nucleoside neuropathy, and infl ammatory demyelinating neuropathy. HIV-associated distal sensory polyneuropathy (also called predominantly sensory neuropathy, or distal symmetrical peripheral neuropathy) is the most common neurological problem in AIDS, with variable incidences in diff erent reports ranging from 19% to 66% (6, 7) . Th e risk factors for HIV-associated distal sensory polyneuropathy are older age, history of alcohol abuse, advanced HIV disease, prior use of a neurotoxic antiretroviral drug, and diabetes mellitus (8, 9) . Infl ammatory demyelinating neuropathy, on the other hand, is less common and can occur at various stages of the disease, requiring diff erent therapeutic approaches.
Both patients presented with an ascending paralysis typically described with clinical GBS. GBS generally follows an infectious prodrome, resulting in an augmented immune response, which cross-reacts with axolemmal or Schwann cell antigens, leading to peripheral nerve damage believed to be due to molecular mimicry. Th e clinical features of GBS are progressive, ascending, fairly symmetric muscle weakness, typically with absent refl exes. Th e severity of symptoms can vary from mild to profound weakness of all extremities and involving respiratory muscles, resulting in respiratory failure requiring intubation. Respiratory failure requiring ventilator support occurs in 10% to 30% of the cases (10) . Symptoms can also include tachycardia, urinary retention, labile blood pressure, arrhythmias, and paresthesias more commonly seen on fi ngertips and feet and can include autonomic instability in severe cases. Th e hallmark laboratory fi nding is albuminocytologic dissociation on the CSF with a near normal white blood cell count seen in up to 66% of patients (11) . Treatment for GBS typically involves IVIG or plasmapheresis, which have been shown to have similar outcomes. In our fi rst patient, intrathecal IgG synthesis was dramatically elevated, suggesting an ongoing immune-mediated process, which did not improve until his viral load came down. Notably, he recovered very rapidly (walking within a week after tetraplegia). Th is was much faster than could be expected in typical GBS patients who have signifi cant changes, both demyelinating and axonal, on NCS/EMG.
GBS in an HIV/AIDS patient was fi rst described in 1985 (12) . GBS may occur in HIV-infected patients at the time of seroconversion, even with normal CD4 counts, and can be the presenting symptom or seen in the setting of the immune reconstitution syndrome (13) (14) (15) (16) . Nucleoside analogue reverse transcriptase inhibitors (NRTIs), a backbone component of HAART, have also been related to GBS in HIV-infected individuals in association with the immune reconstitution syndrome. Twenty-two cases of GBS associated with stavudine (NRTI) therapy have been reported (17) (18) (19) .
Several mechanisms have been proposed regarding GBS in HIV-infected patients. Proposed mechanisms include a direct action of HIV on the nerve by neurotropic strains or formation of autoantibodies against myelin secondary to the abnormal immunoregulation caused by the HIV infection (20) . In the setting of immune reconstitution syndrome, there is a reemergence of previously anergic lymphocytes upon viral suppression with HAART (13) (14) (15) (16) . Cell-mediated immunity is known to play a major role in the pathogenesis of GBS. Th e clinical features of GBS in HIV-infected patients are similar to those in HIV-negative people. However, HIV GBS may be associated with more frequent recurrent episodes and progression to CIDP (21) .
In our fi rst case, the onset of rapidly progressive ascending paralysis coincided with the acute retroviral syndrome of HIV. Th is patient continued to worsen despite IVIG therapy and plasma exchange and only improved with the initiation of HAART and reduction in the viral load. We have not found any previous reports specifi cally addressing the effi cacy of either IVIG or plasmapheresis in the setting of acute retroviral syndrome, but previously reported cases and our fi rst case suggest that antiretroviral treatment is preferable especially if CSF fi ndings show the presence of meningeal infl ammation. In our second case, the patient with chronic HIV infection had clinical symptoms consistent with AIDP and ultimately CIDP with modest recovery only seen with IVIG. IVIG has been shown to speed the course of recovery in patients with GBS and HIV seropositivity. Reports of effi cacy range from ineff ective or mild benefi t to a great response (22) . In the fi rst case, mycoplasma tested positive and in the second case cytomegalovirus was positive. Both cytomegalovirus and mycoplasma have been implicated in ascending paralysis. It is fairly common to have several potential causes for similar presentations in HIV patients with neurological complications, which exemplifi es the complexity of HIV patients.
